SCIENTURE HOLDINGS, INC. Deferred Offering Costs
SCIENTURE HOLDINGS, INC. (SCNX) had Deferred Offering Costs of $47.38 thousand as of 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-13
- 2026-03-31: Deferred Offering Costs $47.38K.
- 2025-12-31: Deferred Offering Costs $47.38K.
- 2025-06-30: Deferred Offering Costs $554.59K.
- 2024-12-31: Deferred Offering Costs $534.80K.
| Period end | Deferred Offering Costs |
|---|---|
| 2026-03-31 | $47.38K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $47.38K 10-Q · filed 2026-08-13 |
| 2025-06-30 | $554.59K 10-Q · filed 2026-08-13 |
| 2024-12-31 | $534.80K 10-Q · filed 2026-08-13 |
| 2024-09-30 | $69.44K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $69.44K 10-Q · filed 2024-08-09 |
| 2021-09-30 | $78.00K 10-Q · filed 2021-10-25 |
| 2019-12-31 | $88.21K 10-Q · filed 2020-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |